Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

Pestell TG, Jiao X, Kumar M, Peck AR, Prisco M, Deng S, Li Z, Ertel A, Casimiro MC, Ju X, Di Rocco A, Di Sante G, Katiyar S, Shupp A, Lisanti MP, Jain P, Wu K, Rui H, Hooper DC, Yu Z, Goldman AR, Speicher DW, Laury-Kleintop L, Pestell RG.

Oncotarget. 2017 Aug 4;8(47):81754-81775. doi: 10.18632/oncotarget.19953. eCollection 2017 Oct 10.

2.

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Body S, Esteve-Arenys A, Miloudi H, Recasens-Zorzo C, Tchakarska G, Moros A, Bustany S, Vidal-Crespo A, Rodriguez V, Lavigne R, Com E, Casanova I, Mangues R, Weigert O, Sanjuan-Pla A, Menéndez P, Marcq B, Picquenot JM, Pérez-Galán P, Jardin F, Roué G, Sola B.

Sci Rep. 2017 Oct 24;7(1):13946. doi: 10.1038/s41598-017-14222-1.

3.

Cyclin D1 promotes tumor cell invasion and metastasis by cytoplasmic mechanisms.

Fusté NP, Ferrezuelo F, Garí E.

Mol Cell Oncol. 2016 Jun 27;3(5):e1203471. eCollection 2016.

4.

Cyclin D1, cancer progression, and opportunities in cancer treatment.

Qie S, Diehl JA.

J Mol Med (Berl). 2016 Dec;94(12):1313-1326. Epub 2016 Oct 2. Review.

5.

Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin.

Fusté NP, Fernández-Hernández R, Cemeli T, Mirantes C, Pedraza N, Rafel M, Torres-Rosell J, Colomina N, Ferrezuelo F, Dolcet X, Garí E.

Nat Commun. 2016 May 16;7:11581. doi: 10.1038/ncomms11581.

6.

Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer.

Fusté NP, Castelblanco E, Felip I, Santacana M, Fernández-Hernández R, Gatius S, Pedraza N, Pallarés J, Cemeli T, Valls J, Tarres M, Ferrezuelo F, Dolcet X, Matias-Guiu X, Garí E.

Oncotarget. 2016 May 10;7(19):26979-91. doi: 10.18632/oncotarget.8876.

7.

Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases.

Hydbring P, Malumbres M, Sicinski P.

Nat Rev Mol Cell Biol. 2016 May;17(5):280-92. doi: 10.1038/nrm.2016.27. Epub 2016 Apr 1. Review.

8.

Aminomethylphosphonic acid inhibits growth and metastasis of human prostate cancer in an orthotopic xenograft mouse model.

Parajuli KR, Zhang Q, Liu S, You Z.

Oncotarget. 2016 Mar 1;7(9):10616-26. doi: 10.18632/oncotarget.7055.

9.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Feb 2;7(5):5383-400. doi: 10.18632/oncotarget.6579. Erratum in: Oncotarget. 2016 Sep 27;7(39):64526.

10.

Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Náger M, Santacana M, Bhardwaj D, Valls J, Ferrer I, Nogués P, Cantí C, Herreros J.

Cell Cycle. 2015;14(22):3644-55. doi: 10.1080/15384101.2015.1104443.

11.

Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells.

Casimiro MC, Di Sante G, Ju X, Li Z, Chen K, Crosariol M, Yaman I, Gormley M, Meng H, Lisanti MP, Pestell RG.

Cancer Res. 2016 Jan 15;76(2):329-38. doi: 10.1158/0008-5472.CAN-15-0999. Epub 2015 Nov 18.

12.

Elevated DNA polymerase iota (Poli) is involved in the acquisition of aggressive phenotypes of human esophageal squamous cell cancer.

Sun H, Zou S, Zhang S, Liu B, Meng X, Li X, Yu J, Wu J, Zhou J.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):3591-601. eCollection 2015.

13.

Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1.

Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH, Lee H, Shin CH, Joung JG, Kim DH, Joo KM, Kim HH.

Oncotarget. 2015 Aug 21;6(24):20434-48.

14.

Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis.

Casimiro MC, Di Sante G, Crosariol M, Loro E, Dampier W, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, Fortina P, Cardiff RD, Tozeren A, Knudsen ES, Arnold A, Pestell RG.

Oncotarget. 2015 Apr 20;6(11):8525-38.

15.

Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors.

Bendris N, Lemmers B, Blanchard JM.

Cell Cycle. 2015;14(12):1786-98. doi: 10.1080/15384101.2014.998085. Review.

16.

The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.

Chen K, Wu K, Jiao X, Wang L, Ju X, Wang M, Di Sante G, Xu S, Wang Q, Li K, Sun X, Xu C, Li Z, Casimiro MC, Ertel A, Addya S, McCue PA, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG.

Cancer Res. 2015 May 15;75(10):1992-2004. doi: 10.1158/0008-5472.CAN-14-0611. Epub 2015 Mar 13.

17.

Different effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion.

Qiao X, Roth I, Féraille E, Hasler U.

Cell Cycle. 2014;13(19):3059-75. doi: 10.4161/15384101.2014.949091.

18.

Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/β-catenin signaling pathway.

Xu X, Mao W, Chen Q, Zhuang Q, Wang L, Dai J, Wang H, Huang Z.

PLoS One. 2014 Sep 18;9(9):e107463. doi: 10.1371/journal.pone.0107463. eCollection 2014.

19.

Cyclin D1 integrates estrogen-mediated DNA damage repair signaling.

Li Z, Chen K, Jiao X, Wang C, Willmarth NE, Casimiro MC, Li W, Ju X, Kim SH, Lisanti MP, Katzenellenbogen JA, Pestell RG.

Cancer Res. 2014 Jul 15;74(14):3959-70. doi: 10.1158/0008-5472.CAN-13-3137. Epub 2014 May 15.

20.

miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1.

Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y, Zhao Q, Ren T, Ju X, Gutman E, Wang G, Addya S, Li T, Xiang Z, Wang C, Yang X, Yang X, Pestell R.

Oncotarget. 2014 Feb 28;5(4):1083-90.

Supplemental Content

Support Center